Director
CurrentPathology and Toxicology yConsultancy. Supporting Early Discovery - exposure models benchmarked to relevant hazard endpoints - aiding molecule selection. The use of surrogate systems to support chemistry designBiopharma target identification - ISH and IHCRegulatory toxicology Studies - all stages of the development programme.Product Life Cycle Management - including MoA exploration and Non Human Relevance Frameworks. Research Projects - to explore and understand carcinogenesis, developmental anomalies, target organ toxicity etcRetrospective evaluation of FFPE tissue from existing studies - IHC, ISH (RNA scope), Image Analysis, microarrays etc